Autopsy report · NCT05740449

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

“Company stopped development and production of one of the IMP's.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Princess Maxima Center for Pediatric Oncology

Sponsor type

University, hospital or other

Conditions

Acute Lymphoblastic Leukemia, in Relapse; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Interventions

Decitabine; Venetoclax; Navitoclax; intrathecal chemotherapy

Participants

0

Sites

1

Countries

Netherlands

Trials that died the same way

• Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV
  “Study not started as the IMP is re-worked by the manufacturer” (65% match in meaning)
• Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer
  “Production of the IMP (plasmid AMEP) has been terminated by the supplier (BioAlliance Pharma)” (63% match in meaning)
• The Study for Evaluate of Satety and Dfficacy of Hemostatic Device
  “The company stopped manufacturing the product” (61% match in meaning)
• A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
  “The development was stopped due to company's strategy consideration” (61% match in meaning)
• Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
  “Product development halted for business reasons.” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.